

Stuart T Haines

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1541208/publications.pdf>

Version: 2024-02-01

99
papers

2,078
citations

293460

24
h-index

286692

43
g-index

101
all docs

101
docs citations

101
times ranked

2140
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of an Entrustment-Supervision Assessment Tool for Pharmacy Experiential Education Using Stakeholder Focus Groups. <i>American Journal of Pharmaceutical Education</i> , 2022, 86, 8523.	0.7	7
2	Situational judgment tests: An introduction for clinician educators. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 67-74.	0.5	6
3	Improving the quality of clinical pharmacy practice research. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 386-387.	0.5	0
4	The clinical educator's guide to fostering learner motivation: AMEE Guide No. 137. <i>Medical Teacher</i> , 2021, 43, 492-500.	1.0	10
5	Critical moments in student learning on international advanced pharmacy practice experiences. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 672-677.	0.4	1
6	How to use the Delphi method to aid in decision making and build consensus in pharmacy education. <i>Currents in Pharmacy Teaching and Learning</i> , 2021, 13, 1376-1385.	0.4	25
7	Entrustable Professional Activities (EPAs) for Global Health. <i>Academic Medicine</i> , 2021, 96, 402-408.	0.8	11
8	The Impact of Two Longitudinal Professionalism Courses on Student Pharmacists' Empathy. <i>American Journal of Pharmaceutical Education</i> , 2021, 85, 8083.	0.7	4
9	Address of the 2021-2022 President-elect at the 2021 Virtual Annual Meeting of the American Association of Colleges of Pharmacy. <i>American Journal of Pharmaceutical Education</i> , 2021, 85, 8837.	0.7	1
10	Getting beyond learner reactions: elevating our scholarship about teaching and learning. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 130-132.	0.5	5
11	Co-curricular assessment plan for developing pharmacy professionals (RxPro) after the first professional year. <i>Currents in Pharmacy Teaching and Learning</i> , 2020, 12, 291-296.	0.4	5
12	Striving for excellence in experiential education. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 692-695.	0.5	0
13	Striving for excellence in experiential education. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 678-691.	0.5	12
14	Residency projects belong in journals not filing cabinets. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 717-720.	0.5	2
15	Global Health Learning Outcomes in Pharmacy Students Completing International Advanced Pharmacy Practice Experiences. <i>American Journal of Pharmaceutical Education</i> , 2020, 84, 7586.	0.7	16
16	Global Health Learning Outcomes by Country Location and Duration for International Experiences. <i>American Journal of Pharmaceutical Education</i> , 2020, 84, 7682.	0.7	8
17	Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 913-921.	0.5	1
18	Entrustable Professional Activities: What, why, who, when, how, and what now?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 95-97.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 342-349.	0.5	3
20	Pharmacy Student Perceptions of the Entrustable Professional Activities. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7274.	0.7	14
21	Implementation Science to Advance Care Delivery: A Primer for Pharmacists and Other Health Professionals. <i>Pharmacotherapy</i> , 2018, 38, 490-502.	1.2	57
22	It's Time to Dismantle CE and Build a CPI System. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 6985.	0.7	4
23	Validation of the entrustable professional activities for new pharmacy graduates. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1922-1929.	0.5	23
24	Impact of a national antimicrobial stewardship mentoring program: Insights and lessons learned. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 224-231.	0.5	16
25	<sc>ACCP</sc> Template for Evaluating a Clinical Pharmacist. <i>Pharmacotherapy</i> , 2017, 37, e21-e29.	1.2	16
26	Improved Learning Outcomes After Flipping a Therapeutics Module: Results of a Controlled Trial. <i>Academic Medicine</i> , 2017, 92, 1786-1793.	0.8	27
27	Recommendations for Evaluating Practice-Related Activities of Pharmacy Faculty. <i>Annals of Pharmacotherapy</i> , 2017, 51, 345-353.	0.9	2
28	Improving peer review: What reviewers can do. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 2080-2084.	0.5	18
29	Improving peer review: What authors can do. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 2076-2079.	0.5	7
30	Improving peer review: What journals can do. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 2086-2089.	0.5	13
31	Core Entrustable Professional Activities for New Pharmacy Graduates. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, S2.	0.7	213
32	Describing Entrustable Professional Activities Is Merely the First Step. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, 18.	0.7	24
33	Processes and Metrics to Evaluate Faculty Practice Activities at US Schools of Pharmacy. <i>American Journal of Pharmaceutical Education</i> , 2016, 80, 60.	0.7	6
34	Treatment Approach to Patients With Severe Insulin Resistance. <i>Clinical Diabetes</i> , 2016, 34, 97-104.	1.2	39
35	Best practices for safe use of insulin pen devices in hospitals: Recommendations from an expert panel Delphi consensus process. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S4-S16.	0.5	10
36	Beliefs and behaviors of professionally engaged pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 405-411.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Facilitating the safe use of insulin pens in hospitals through a mentored quality-improvement program. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S17-S31.	0.5	5
38	Best practices in ensuring the safe use of insulin pens in the hospital: Introduction. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, S2-S3.	0.5	0
39	An objective structured teaching exercise (OSTE) for preceptor development. <i>Currents in Pharmacy Teaching and Learning</i> , 2015, 7, 627-634.	0.4	9
40	Understanding insulin management: Role of the pharmacist. <i>Pharmacy Today</i> , 2014, 20, 85-95.	0.0	4
41	A Checklist for the Development of Faculty Mentorship Programs. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 98.	0.7	50
42	Faculty Development: Who, What, Why, Where, When, and How?. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 97.	0.7	3
43	Does Board Certification Really Matter?. <i>Pharmacotherapy</i> , 2014, 34, 799-802.	1.2	5
44	Prevalence of and Factors That Influence Board Certification Among Pharmacy Practice Faculty at United States Colleges and Schools of Pharmacy. <i>Pharmacotherapy</i> , 2013, 33, 105-111.	1.2	13
45	An objective structured teaching examination (OSTE) for faculty development. <i>Currents in Pharmacy Teaching and Learning</i> , 2013, 5, 616-619.	0.4	6
46	Anticoagulation; New Pharmacologic Methods to Prevent Venous Thromboembolism in Older Adults: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2013, 47, 605-616.	0.9	3
47	Best Practice Strategies for Effective Use of Questions as a Teaching Tool. <i>American Journal of Pharmaceutical Education</i> , 2013, 77, 155.	0.7	161
48	Weighing the Potential Benefits and Risks of Antidiabetic Agents in Older Adults. <i>Diabetes Spectrum</i> , 2012, 25, 172-179.	0.4	2
49	Vitamin <sc>D</sc> Supplementation: What's Known, What to Do, and What's Needed. <i>Pharmacotherapy</i> , 2012, 32, 354-382.	1.2	59
50	Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. <i>Journal of Ethnopharmacology</i> , 2011, 134, 422-428.	2.0	133
51	Board Certification of Pharmacist Specialists: American College of Clinical Pharmacy. <i>Pharmacotherapy</i> , 2011, 31, 1146-1149.	1.2	27
52	Substituting Warfarin Products: What's the Source of the Problem?. <i>Annals of Pharmacotherapy</i> , 2011, 45, 807-809.	0.9	7
53	Scoring Objective Structured Clinical Examinations Using Video Monitors or Video Recordings. <i>American Journal of Pharmaceutical Education</i> , 2010, 74, 44.	0.7	25
54	Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 42-48.	0.5	27

#	ARTICLE	IF	CITATIONS
55	Protected professional practice evaluation: A continuous quality-improvement process. American Journal of Health-System Pharmacy, 2010, 67, 1933-1940.	0.5	7
56	Improving the quality of care for patients at risk for venous thromboembolism. American Journal of Health-System Pharmacy, 2010, 67, S3-S8.	0.5	0
57	Clinical and management challenges in preventing venous thromboembolism in health systems: A case-based panel discussion. American Journal of Health-System Pharmacy, 2010, 67, S26-S30.	0.5	1
58	Improving anticoagulant use for prevention of venous thromboembolism Introduction. American Journal of Health-System Pharmacy, 2010, 67, S2-S3.	0.5	2
59	Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Current Medical Research and Opinion, 2010, 26, 231-238.	0.9	68
60	Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps. Journal of the American Pharmacists Association: JAPhA, 2009, 49, e1-e17.	0.7	21
61	Key Articles and Guidelines for the Prevention of Venous Thromboembolism. Pharmacotherapy, 2009, 29, 410-458.	1.2	19
62	The Impact of Advanced Pharmacy Practice Experiences on Students' Readiness for Self-directed Learning. American Journal of Pharmaceutical Education, 2009, 73, 65.	0.7	24
63	Addressing Competencies for the Future in the Professional Curriculum. American Journal of Pharmaceutical Education, 2009, 73, 156.	0.7	114
64	Patient education and monitoring recommendations for the use of glucagon-like peptide-1 receptor agonists. Journal of Family Practice, 2009, 58, S44-8.	0.2	0
65	Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy, 2008, 28, 170-192.	1.2	29
66	Developing a Business-Practice Model for Pharmacy Services in Ambulatory Settings. Pharmacotherapy, 2008, 28, 285-285.	1.2	48
67	Multidisciplinary Interventions: Mapping New Horizons in Diabetes Care. The Diabetes Educator, 2008, 34, 78S-89S.	2.6	7
68	Considerations in using anticoagulant therapy in special patient populations. American Journal of Health-System Pharmacy, 2008, 65, S13-S21.	0.5	8
69	Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. American Journal of Health-System Pharmacy, 2008, 65, S22-S28.	0.5	5
70	Challenges in managing venous thromboembolism and acute coronary syndrome: Case studies of the use of antithrombotic and antiplatelet therapies. American Journal of Health-System Pharmacy, 2008, 65, S3-S4.	0.5	2
71	Improving the use of anticoagulant therapies in acutely ill medical patients. American Journal of Health-System Pharmacy, 2008, 65, S5-S12.	0.5	9
72	Report of the 2007-2008 Professional Affairs Committee. American Journal of Pharmaceutical Education, 2008, 72, S5.	0.7	2

#	ARTICLE	IF	CITATIONS
73	Bias in <i>AJHP</i> supplements. American Journal of Health-System Pharmacy, 2008, 65, 2329-2330.	0.5	0
74	Emerging Treatments for Patients With Type 2 Diabetes. The Diabetes Educator, 2007, 33, 105S-110S.	2.6	0
75	Case Presentation: A Patient With Type 2 Diabetes. The Diabetes Educator, 2007, 33, 114S-116S.	2.6	0
76	Making Residency Training an Expectation for Pharmacists in Direct Patient Care Roles. American Journal of Pharmaceutical Education, 2007, 71, 71.	0.7	20
77	Emerging Treatments for Patients with Type 2 Diabetes. The Diabetes Educator, 2007, 33, 105S-110S.	2.6	2
78	Anticoagulation Strategies for Treatment of Ischemic Stroke and Antiphospholipid Syndrome: Case Report and Review of the Literature. Pharmacotherapy, 2006, 26, 1518-1525.	1.2	5
79	Introduction: Addressing Cardiometabolic Risk. Pharmacotherapy, 2006, 26, 1S-2S.	1.2	0
80	Evaluating and Treating Cardiometabolic Risk Factors: A Case Discussion. Pharmacotherapy, 2006, 26, 32S-41S.	1.2	0
81	ASHP Therapeutic Position Statement on the Treatment of Hypertension. American Journal of Health-System Pharmacy, 2006, 63, 1074-1080.	0.5	0
82	Development and Validation of an Instrument to Determine Patient Knowledge: The Oral Anticoagulation Knowledge Test. Annals of Pharmacotherapy, 2006, 40, 633-638.	0.9	80
83	Current and emerging treatment options for venous thrombosis: A case discussion. American Journal of Health-System Pharmacy, 2005, 62, 593-605.	0.5	0
84	Update on The Prevention of Venous Thromboembolism. American Journal of Health-System Pharmacy, 2004, 61, S5-S11.	0.5	0
85	Dosing of Unfractionated Heparin in Acute Coronary Syndromes. Pharmacotherapy, 2004, 24, 1681-1691.	1.2	1
86	White Paper: Value of Specialty Certification in Pharmacy. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 612-620.	0.7	40
87	Academic Pharmacy's Role in Advancing Practice and Assuring Quality in Experiential Education: Report of the 2003-2004 Professional Affairs Committee. American Journal of Pharmaceutical Education, 2004, 68, S8.	0.7	35
88	The Diabetes Epidemic: Can We Stop the Spread?. Pharmacotherapy, 2003, 23, 1227-1231.	1.2	5
89	The Mentor-Protégé Relationship. American Journal of Pharmaceutical Education, 2003, 67, 82.	0.7	47
90	Venous thromboembolism: Pathophysiology and clinical presentation. American Journal of Health-System Pharmacy, 2003, 60, S3-S5.	0.5	24

#	ARTICLE	IF	CITATIONS
91	National Diabetes Education Program: Teaming Up to Prevent Diabetes and Its Complications. Journal of the American Pharmacists Association, 2002, 42, 802-804.	0.6	0
92	Relationship between the pharmaceutical industry and pharmacy practitioners: Undue influence?. American Journal of Health-System Pharmacy, 2002, 59, 1871-1874.	0.5	9
93	Low-Molecular-Weight Heparins for Venous Thromboembolism—Making an Evidence-Based Treatment Choice. Pharmacotherapy, 2001, 21, 71S-72S.	1.2	2
94	Prevention of Venous Thromboembolism. Archives of Internal Medicine, 2000, 160, 334.	4.3	134
95	Reflections on generic warfarin. American Journal of Health-System Pharmacy, 1998, 55, 729-733.	0.5	15
96	Diagnosis of deep vein thrombosis. American Journal of Health-System Pharmacy, 1997, 54, 66-74.	0.5	13
97	Thrombosis and the Pharmacology of Antithrombotic Agents. Annals of Pharmacotherapy, 1995, 29, 892-905.	0.9	41
98	Treating Constipation in the Patient With Diabetes. The Diabetes Educator, 1995, 21, 223-232.	2.6	10
99	Treatment of Infantile Spasms. Annals of Pharmacotherapy, 1994, 28, 779-791.	0.9	27